Merck & Co., Inc., reports its vision for Organon

Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) reported the vision, focus and business model for its new standalone company, Organon.  Merck & Co., Inc., disclosed that Organon with have a direct sales presence in 58 markets, with key growth drivers in Organon’s biosimilars portfolio expected to be Renflexis® (biosimilar infliximab), Aybintio® (biosimilar bevacizumab) and Hadlima® (biosimilar adalimumab).